Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

534 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer.
Andreis D, Bonardi S, Allevi G, Aguggini S, Gussago F, Milani M, Strina C, Spada D, Ferrero G, Ungari M, Rocca A, Nanni O, Roviello G, Berruti A, Harris AL, Fox SB, Roviello F, Polom K, Bottini A, Generali D. Andreis D, et al. Among authors: berruti a. Breast. 2016 Oct;29:55-61. doi: 10.1016/j.breast.2016.07.003. Epub 2016 Jul 16. Breast. 2016. PMID: 27428471
Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial.
Dogliotti L, Berruti A, Buniva T, Zola P, Baù MG, Farris A, Sarobba MG, Bottini A, Alquati P, Deltetto F, Gosso P, Monzeglio C, Moro G, Sussio M, Perroni D. Dogliotti L, et al. Among authors: berruti a. J Clin Oncol. 1996 Apr;14(4):1165-72. doi: 10.1200/JCO.1996.14.4.1165. J Clin Oncol. 1996. PMID: 8648371 Clinical Trial.
Prognostic factors in metastatic breast cancer patients obtaining objective response or disease stabilization after first-line chemotherapy with epirubicin. Evidence for a positive effect of maintenance hormonal therapy on overall survival.
Berruti A, Zola P, Buniva T, Baù MG, Farris A, Sarobba MG, Bottini A, Tampellini M, Durando A, Destefanis M, Monzeglio C, Moro G, Sussio M, Perroni D, Dogliotti L. Berruti A, et al. Anticancer Res. 1997 Jul-Aug;17(4A):2763-8. Anticancer Res. 1997. PMID: 9252712 Clinical Trial.
Cytotoxic and antiproliferative activity of the CMF regimen administered in association with tamoxifen as primary chemotherapy in breast cancer patients.
Bottini A, Berruti A, Bersiga A, Brunelli A, Brizzi MP, Di Marco B, Cirillo F, Tampellini M, Bolsi G, Aguggini S, Betri E, Filippini L, Bertoli A, Alquati P, Dogliotti L. Bottini A, et al. Among authors: berruti a. Int J Oncol. 1998 Aug;13(2):385-90. doi: 10.3892/ijo.13.2.385. Int J Oncol. 1998. PMID: 9664137 Clinical Trial.
Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines.
Berruti A, Sperone P, Bottini A, Gorzegno G, Lorusso V, Brunelli A, Botta M, Tampellini M, Donadio M, Mancarella S, De Lena M, Alquati P, Dogliotti L. Berruti A, et al. J Clin Oncol. 2000 Oct 1;18(19):3370-7. doi: 10.1200/JCO.2000.18.19.3370. J Clin Oncol. 2000. PMID: 11013277 Clinical Trial.
Paclitaxel administration on days 1 and 8 every 21 days in anthracycline-pretreated metastatic breast cancer patients. A multicenter phase II trial.
Donadio M, Manzin E, Berruti A, Bottini A, Gorzegno G, Danese S, DeFabiani E, Sarobba MG, Lorusso V, Castiglione F, Moro G, Bertetto O, Bumma C, Dogliotti L. Donadio M, et al. Among authors: berruti a. Cancer Chemother Pharmacol. 2001 May;47(5):391-6. doi: 10.1007/s002800000247. Cancer Chemother Pharmacol. 2001. PMID: 11391853 Clinical Trial.
534 results